可溶性尿激酶纤溶酶原激活物受体与血液透析患者全因及心血管死亡的关系
在意大利南部35个透析中心纳入1038例血液透析患者的前瞻性队列中,随访2.9年,血浆suPAR水平独立预测全因死亡(第三vs第一三分位HR=1.91,95%CI 1.47-2.48,P<0.001)、心血管死亡(HR=1.47,95%CI 1.03-2.09,P=0.03)和非心血管死亡(HR=1.94,95%CI 1.28-2.93,P=0.002)。但suPAR对基于简单临床变量的简约模型仅增加有限的预后判别和重分类能力。
要点
- suPAR独立预测血液透析患者全因、心血管及非心血管死亡。
- suPAR与女性、年龄、透析龄、心血管合并症、碱性磷酸酶、白蛋白和BMI独立相关。
- suPAR对简约临床模型的预后判别和重分类改善有限。
核心结论
- 在大型未选择的血液透析人群中,suPAR稳健预测全因死亡以及心血管和非心血管死亡。
- 需要干预性研究来明确检验suPAR是否因果性参与该人群临床结局的假设。
研究设计与样本
- PROGREDIRE研究是一项在意大利南部2个地区35个透析中心开展的队列研究。
- 共纳入1038例血液透析患者,随访2.9年(四分位距1.7-4.2年)。
- 采用R&D酶联免疫吸附试验(ELISA)测定血浆suPAR水平。
主要发现
- suPAR与女性(β=-0.160)、年龄(β=0.216)、透析龄(β=0.264)、心血管合并症(β=0.105)、碱性磷酸酶(β=0.136)、白蛋白(β=-0.147)和体重指数(BMI;β=0.174)独立相关(均P<0.006)。
- 完全校正分析中,suPAR第三三分位 vs 第一三分位预测全因死亡HR=1.91(95%CI 1.47-2.48,P<0.001)。
- suPAR第三三分位 vs 第一三分位预测心血管死亡HR=1.47(95%CI 1.03-2.09,P=0.03)。
- suPAR第三三分位 vs 第一三分位预测非心血管死亡HR=1.94(95%CI 1.28-2.93,P=0.002)。
- 上述关系不受糖尿病或其他危险因素影响。
关键数值与推荐
- suPAR对基于简单临床变量的简约模型仅增加有限的预后风险判别和重分类能力。
临床怎么用
- suPAR可作为血液透析患者全因及心血管死亡的风险分层生物标志物。
- 但因其对简约临床模型的增量预后价值有限,暂不宜单独用于临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The soluble receptor of urokinase plasminogen activator (suPAR) is an innate immunity/inflammation biomarker predicting cardiovascular (CV) and non-CV events in various conditions, including type 2 diabetic patients on dialysis. However, the relationship between suPAR and clinical outcomes in the hemodialysis population at large has not been tested. METHODS: We measured plasma suPAR levels (R&D enzyme-linked immunosorbent assay [ELISA]) in 1038 hemodialysis patients with a follow-up of 2.9 years (interquartile range = 1.7-4.2) who were enrolled in the PROGREDIRE study, a cohort study involving 35 dialysis units in 2 regions in Southern Italy. RESULTS: suPAR was strongly (P < 0.001) and independently related to female gender (β = -0.160), age (β = 0.216), dialysis vintage (β = 0.264), CV comorbidities (β = 0.105), alkaline phosphatase (β = 0.136), albumin (β = -0.147), and body mass index (BMI; β = 0.174) (all P < 0.006). In fully adjusted analyses, suPAR tertiles predicted the risk of all-cause mortality (third tertile vs. first tertile hazard ratio (HR) = 1.91, 95% confidence interval (CI) = 1.47 - 2.48, P < 0.001), CV mortality (HR = 1.47, 95% CI = 1.03-2.09, P = 0.03), and non-CV mortality (HR = 1.94, 95% CI = 1.28-2.93, P = 0.002); these relationships were not modified by diabetes or other risk factors. suPAR added only modest prognostic risk discrimination and reclassification power for these outcomes to parsimonious models based on simple clinical variables. CONCLUSION: In conclusion, suPAR robustly predicted all-cause and both CV and non-CV mortality in a large unselected hemodialysis population. Intervention studies are needed to definitively test the hypothesis that suPAR is causally implicated in clinical outcomes in this population.
引用
- Torino C, Pizzini P, Cutrupi S, et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients. Kidney Int Rep. 2018. PMID: 30197976. doi:10.1016/j.ekir.2018.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。